Related references
Note: Only part of the references are listed.Deciphering Multiple Sclerosis Progression
Virginia Meca-Lallana et al.
FRONTIERS IN NEUROLOGY (2021)
Impact of Age on Multiple Sclerosis Disease Activity and Progression
Burcu Zeydan et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2020)
Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis
Jacqueline A. Nicholas et al.
BMC NEUROLOGY (2020)
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
Marcello Moccia et al.
BMC HEALTH SERVICES RESEARCH (2020)
Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
Yinan Zhang et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)
The prevalence of MS in the United States A population-based estimate using health claims data
Mitchell T. Wallin et al.
NEUROLOGY (2019)
Epidemiology and treatment of multiple sclerosis in elderly populations
Caila B. Vaughn et al.
NATURE REVIEWS NEUROLOGY (2019)
Validation of an algorithm to detect severe MS relapses in administrative health databases
James John Marriott et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1
Anthony Traboulsee et al.
BMC NEUROLOGY (2018)
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Ann Marie Weideman et al.
FRONTIERS IN NEUROLOGY (2017)
Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study
Meritxell Sabido-Espin et al.
BMC NEUROLOGY (2017)
Aging and multiple sclerosis
Shaik Ahmed Sanai et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Long-Term Adherence to IFN Beta-1α Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
O. Fernandez et al.
PLOS ONE (2016)
Aging and multiple sclerosis
Shaik Ahmed Sanai et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Adherence and persistence to drug therapies for multiple sclerosis: A population-based study
Charity Evans et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
Raed Alroughani et al.
PLOS ONE (2016)
Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review
Tomas Kalincik
NEUROEPIDEMIOLOGY (2015)
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study
Kerstin Hansen et al.
PLOS ONE (2015)
Relapses and disability accumulation in progressive multiple sclerosis
M. Mateo Paz Soldan et al.
NEUROLOGY (2015)
Multiple Sclerosis: Current Knowledge and Future Outlook
Christian P. Kamm et al.
EUROPEAN NEUROLOGY (2014)
Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
Oscar Fernandez et al.
PLOS ONE (2012)
Age and disability accumulation in multiple sclerosis
A. Scalfari et al.
NEUROLOGY (2011)
Good and poor adherence: optimal cut-point for adherence measures using administrative claims data
Sudeep Karve et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Factors that influence adherence with disease-modifying therapy in MS
Katherine Treadaway et al.
JOURNAL OF NEUROLOGY (2009)
Methods for evaluation of medication adherence and persistence using automated databases
Susan E. Andrade et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2006)
Share Paper
